Bevacizumab/fluorouracil/folinic acid/irinotecan

Abstract

S Bevacizumab/fluorouracil/folinic acid/ irinotecanAnaphylactic shock: case report A patient over the age of 70 [sex and age not clearly stated] developed an anaphylactic shock during bevacizumab-FOLFIRI (folinic acid, fluorouracil, irinotecan) therapy [routes not stated]. In 2006, the patient was enrolled in an observational study. During this study, the patient received FOLFIRI [dose not stated] in combination with bevacizumab 5 mg/kg on every 2 weeks for the treatment of unresectable metastatic colorectal cancer. The patient developed an anaphylactic shock related to bevacizumab-FOLFIRI therapy [duration of treatment to reaction onset and outcome not stated].Author comment: "Eighteen patients (16%) had one or several grade III/IV bevacizumab-FOLFIRI treatment-related adverse events." "One patient over the age of 70 presented with anaphylactic shock."